|
Post by peppy on Apr 19, 2018 12:13:28 GMT -5
And don’t forget who is presenting at ADA on behalf of Mannkind. Our very own Dr. K. Perhaps this was MK third catalyst? I don't remember that, but I think that is because it is incorrect information. The study wasn't conducted by Mannkind. The lead author was Dr. Satish Garg of Univ of CO who will presumably be the one presenting. Where did you read/hear that Kendall would be presenting? I believe MNKD has one additional verbal presentation at ADA. Kendall.
|
|
|
Post by dreamboatcruise on Apr 19, 2018 12:25:24 GMT -5
I don't remember that, but I think that is because it is incorrect information. The study wasn't conducted by Mannkind. The lead author was Dr. Satish Garg of Univ of CO who will presumably be the one presenting. Where did you read/hear that Kendall would be presenting? I believe MNKD has one additional verbal presentation at ADA. Kendall. What is he presenting? I can't find him in the advanced program.
|
|
|
Post by mannmade on Apr 19, 2018 12:27:28 GMT -5
My bad as I thought I read somewhere on the board that he would also be present to speak. At a minimum he has the right contacts w ada now that we have the stat study results and the ada has new guidelines for revisions to soc.
|
|
|
Post by peppy on Apr 19, 2018 12:37:23 GMT -5
I believe MNKD has one additional verbal presentation at ADA. Kendall. What is he presenting? I can't find him in the advanced program. dream it was posted by someone somewhere. Something about an additional MNKD presentation at the ADA. I believe it is to be verbal.
|
|
|
Post by mnholdem on Apr 19, 2018 13:54:01 GMT -5
Press release excerpt:
“We are very pleased with the opportunity to present the STAT Study results at the 78th Scientific Sessions of the American Diabetes Association”, stated Dr. Satish Garg (Barbara Davis Center for Diabetes, University of Colorado Denver), senior author and principal investigator of the collaborative multicenter randomized study.
“MannKind welcomes the opportunity to share the results of this collaborative clinical trial and looks forward to pursuing additional analyses to assess the clinical use of Afrezza therapy for mealtime glucose control,” stated David Kendall, MD, Chief Medical Officer of MannKind Corporation. “We believe that the STAT Study results will offer important insights into ways that individuals with diabetes can potentially improve their experience and outcomes by using mealtime inhaled insulin ’in the moment.‘ Our long-term goal is to establish inhaled human insulin as both a useful option and a potential treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
---
It really comes down to how you interpret CMO Dr. Kendall's remarks. Will he join Dr. Garg to "share the results of this collaborative clinical trial" at the ADA Scientific Sessions? The answer is entirely speculative at this point, but it is clear that MannKind plans to share the trial results. Perhaps MannKind's CEO and/or CMO will shed more light on their participation in the two STAT presentations when they speak at May 16 Annual Shareholders Meeting.
|
|
|
Post by dreamboatcruise on Apr 19, 2018 14:16:51 GMT -5
Press release excerpt:
“We are very pleased with the opportunity to present the STAT Study results at the 78th Scientific Sessions of the American Diabetes Association”, stated Dr. Satish Garg (Barbara Davis Center for Diabetes, University of Colorado Denver), senior author and principal investigator of the collaborative multicenter randomized study.
“MannKind welcomes the opportunity to share the results of this collaborative clinical trial and looks forward to pursuing additional analyses to assess the clinical use of Afrezza therapy for mealtime glucose control,” stated David Kendall, MD, Chief Medical Officer of MannKind Corporation. “We believe that the STAT Study results will offer important insights into ways that individuals with diabetes can potentially improve their experience and outcomes by using mealtime inhaled insulin ’in the moment.‘ Our long-term goal is to establish inhaled human insulin as both a useful option and a potential treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
---
It really comes down to how you interpret CMO Dr. Kendall's remarks. Will he join Dr. Garg to "share the results of this collaborative clinical trial" at the ADA Scientific Sessions? The answer is entirely speculative at this point, but it is clear that MannKind plans to share the trial results. Perhaps MannKind's CEO and/or CMO will shed more light on their participation in the two STAT presentations when they speak at May 16 Annual Shareholders Meeting.
I've participated in a lot of conferences and having multiple speakers for one presentation is not normal. Though, I would assume he'll be at the conference and talking to lots of people about the STAT results. Personally I don't think this is a big deal one way or the other. If the STAT study results are credible and impressive (I think they will be) then people will pay attention regardless of who presents (assuming some level of competency of the speaker). Actually, searching the Advanced Program now, nothing for "Garg" turns up. Has someone seen the STAT study listed in the Advanced Program? Is it perhaps only a poster presentation?
|
|
|
Post by celo on Apr 19, 2018 16:59:11 GMT -5
Press release excerpt:
“We are very pleased with the opportunity to present the STAT Study results at the 78th Scientific Sessions of the American Diabetes Association”, stated Dr. Satish Garg (Barbara Davis Center for Diabetes, University of Colorado Denver), senior author and principal investigator of the collaborative multicenter randomized study.
“MannKind welcomes the opportunity to share the results of this collaborative clinical trial and looks forward to pursuing additional analyses to assess the clinical use of Afrezza therapy for mealtime glucose control,” stated David Kendall, MD, Chief Medical Officer of MannKind Corporation. “We believe that the STAT Study results will offer important insights into ways that individuals with diabetes can potentially improve their experience and outcomes by using mealtime inhaled insulin ’in the moment.‘ Our long-term goal is to establish inhaled human insulin as both a useful option and a potential treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
---
It really comes down to how you interpret CMO Dr. Kendall's remarks. Will he join Dr. Garg to "share the results of this collaborative clinical trial" at the ADA Scientific Sessions? The answer is entirely speculative at this point, but it is clear that MannKind plans to share the trial results. Perhaps MannKind's CEO and/or CMO will shed more light on their participation in the two STAT presentations when they speak at May 16 Annual Shareholders Meeting.
I've participated in a lot of conferences and having multiple speakers for one presentation is not normal. Though, I would assume he'll be at the conference and talking to lots of people about the STAT results. Personally I don't think this is a big deal one way or the other. If the STAT study results are credible and impressive (I think they will be) then people will pay attention regardless of who presents (assuming some level of competency of the speaker). Actually, searching the Advanced Program now, nothing for "Garg" turns up. Has someone seen the STAT study listed in the Advanced Program? Is it perhaps only a poster presentation? Yes, I was going to ask the same question. I couldn't find where the STAT study existed in the program. I assumed it was my inability to navigate the online program. If anyone can find it, it would be much appreciated.
|
|
|
Post by agedhippie on Apr 19, 2018 17:19:28 GMT -5
What is he presenting? I can't find him in the advanced program. dream it was posted by someone somewhere. Something about an additional MNKD presentation at the ADA. I believe it is to be verbal. It's an oral presentation - Oral Presentations are grouped by topic or theme and include up to eight presentations. They provide attendees with the most up-to-date basic science and clinical research data in the field of diabetes. Each presentation is 10 minutes in length followed by a 5-minute question and answer period.Oral presentations have the same status as posters, there is some argument as whether posters or oral presentations are more effective. They run in parallel to main stage events so you have to hope your slot is scheduled against a really boring main event Typically oral presentations are not listed because they are minor events and there are a lot of them!
|
|
|
Post by peppy on Apr 19, 2018 17:47:10 GMT -5
dream it was posted by someone somewhere. Something about an additional MNKD presentation at the ADA. I believe it is to be verbal. It's an oral presentation - Oral Presentations are grouped by topic or theme and include up to eight presentations. They provide attendees with the most up-to-date basic science and clinical research data in the field of diabetes. Each presentation is 10 minutes in length followed by a 5-minute question and answer period.Oral presentations have the same status as posters, there is some argument as whether posters or oral presentations are more effective. They run in parallel to main stage events so you have to hope your slot is scheduled against a really boring main event Typically oral presentations are not listed because they are minor events and there are a lot of them! Thank you aged.
|
|
|
Post by digger on Apr 19, 2018 19:08:40 GMT -5
dream it was posted by someone somewhere. Something about an additional MNKD presentation at the ADA. I believe it is to be verbal. It's an oral presentation - Oral Presentations are grouped by topic or theme and include up to eight presentations. They provide attendees with the most up-to-date basic science and clinical research data in the field of diabetes. Each presentation is 10 minutes in length followed by a 5-minute question and answer period.Oral presentations have the same status as posters, there is some argument as whether posters or oral presentations are more effective. They run in parallel to main stage events so you have to hope your slot is scheduled against a really boring main event Typically oral presentations are not listed because they are minor events and there are a lot of them! Ten minutes? Why even bother? But there are two presentations, one oral and one poster -- investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-stat-study-results-accepted-presentation
|
|
|
Post by digger on Apr 19, 2018 19:15:06 GMT -5
|
|
|
Post by compound26 on Apr 20, 2018 10:43:50 GMT -5
Interestingly, there is one presentation in ADA that has something to do with inhaled treatment, though it appears not Mannkind related.
Exploring the Next Frontier in
Diabetes Pharmacology
Peptides Gone “Oral” or Other
Delivery Routes (Transnasal,
Transdermal, Inhaled, etc.) for
Glucose-Lowering Agents
Hugh Smyth, PhD
|
|
|
Post by cjc04 on Apr 20, 2018 10:56:57 GMT -5
Interestingly, there is one presentation in ADA that has something to do with inhaled treatment, though it appears not Mannkind related. Exploring the Next Frontier in Diabetes Pharmacology Peptides Gone “Oral” or Other Delivery Routes (Transnasal, Transdermal, Inhaled, etc.) for Glucose-Lowering Agents Hugh Smyth, PhD LMFAO!!!! WTF!!! I don’t know what is more hilarious, Mannkind not being involved, or “Exploring the Next Frontier” It’s as if Mannkind & Afrezza do not exist and these guys just came up with this idea for the first time.
|
|
|
Post by peppy on Apr 20, 2018 11:19:34 GMT -5
Interestingly, there is one presentation in ADA that has something to do with inhaled treatment, though it appears not Mannkind related. Exploring the Next Frontier in Diabetes Pharmacology Peptides Gone “Oral” or Other Delivery Routes (Transnasal, Transdermal, Inhaled, etc.) for Glucose-Lowering Agents Hugh Smyth, PhD • Example 11. Oral Administration of Disodium FDKP-Insulin Capsules containing the FDKP salt and insulin are taken before a meal. The exact dosage is patient-specific, but generally on the order of approximately 10-150 units of insulin is administered per dose. The subsequent insulin absorption attenuates post-prandial blood glucose excursions. This oral insulin formulation is used to replace pre-meal insulin injections in patients with diabetes. Additionally, insulin absorbed through the gastrointestinal tract mimics endogenous insulin secretion. Endogenous insulin is secreted by the pancreas into the portal circulation. Insulin absorbed following oral administration also goes directly to the portal circulation. Thus, the oral route of insulin administration delivers insulin to its site of action in the liver, offering the potential to control glucose levels while limiting systemic exposure to insulin. Oral insulin delivery using a combination of insulin and the diacid form of FDKP is hindered by the poor solubility of the FDKP diacid in the low pH environment of the gastrointestinal tract. The FDKP salts, however, provide a local buffering effect that facilitates their dissolution in low pH. patentscope.wipo.int/search/en/detail.jsf?docId=US204148335
|
|
|
Post by dreamboatcruise on Apr 20, 2018 11:34:38 GMT -5
Interestingly, there is one presentation in ADA that has something to do with inhaled treatment, though it appears not Mannkind related. Exploring the Next Frontier in Diabetes Pharmacology Peptides Gone “Oral” or Other Delivery Routes (Transnasal, Transdermal, Inhaled, etc.) for Glucose-Lowering Agents Hugh Smyth, PhD LMFAO!!!! WTF!!! I don’t know what is more hilarious, Mannkind not being involved, or “Exploring the Next Frontier” It’s as if Mannkind & Afrezza do not exist and these guys just came up with this idea for the first time. There is no reason they would necessarily have MNKD involved. In fact, given that it is academic presentation on different delivery routes, it would add an air of bias if they brought in company representatives for some but not all things being discussed. I would certainly presume they would mention Afrezza when talking about inhaled option, as to not do so would seem like they aren't very knowledgeable about their topic. Something would be very weird if they didn't mention Afrezza, but no reason from what we know currently to assume they won't.
|
|